Effect of Inhaled Nitric Oxide on Pulmonary Ventilation/Perfusion Ratio Assessed by EIT in Patients With ARDS

Critical Illness Clinical Trial

Official title:

Effect of Inhaled Nitric Oxide on Pulmonary Ventilation/Perfusion Ratio Assessed by Electrical Impedance Tomography in Patients With Acute Respiratory Distress Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05873647
• Other study ID #: INOEIT20230404
• Status: Recruiting
• Start date: May 1, 2023
• Est. completion date: May 1, 2025

Study information

• Verified date: May 2023
• Source: Wuhan Union Hospital, China
• Contact: Xiaojing Zou, prof.
• Phone: +862785351606
• Email: 249126734[@]qq.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Electrical impedance tomography was used to monitor changes in pulmonary perfusion distribution and V/Q ratio before and after iNO in patients with acute respiratory distress syndrome to investigate the factors predicting iNO reactivity and the physiological mechanism underlying changes in oxygenation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: May 1, 2025
• Est. primary completion date: May 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients aged = 18 years;

2. Patients are intubated and mechanically ventilated.

Exclusion Criteria:

1. EIT contraindications such as chest wound dressing, pacemaker installation, defibrillator, etc;

2. With a history of cerebral hemorrhage in the past half year, as well as bleeding in any site of the body;

3. Pneumothorax;

4. Medium or massive pleural effusion;

5. Refractory shock;

6. Pregnant

7. With chronic kidney disease

8. Atrial fibrillation or other malignant arrhythmia leads to a decrease in cardiac output;

9. Failure to sign informed consent

Related Conditions & MeSH terms

• Critical Illness

Locations

Country	Name	City	State
China	Hongling Zhang	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Wuhan Union Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lung ventilation/perfusion ration	Lung ventilation/perfusion ration after iNO assessed by EIT	3 hours
Secondary	Lung perfusion distribution	Lung ventilation/perfusion ration after iNO assessed by EIT	30minutes and 3 hours
Secondary	Shunting	Lung shunting% after iNO assessed by EIT	30minutes and 3 hours
Secondary	Dead space	Lung dead space after iNO assessed by EIT	30minutes and 3 hours
Secondary	Oxygenation index	Oxygenation index= arterial partial pressure of oxygen/fraction of inspired oxygen	30minutes and 3 hours
Secondary	Arterial partial pressure of carbon dioxide (PaCO2)	PaCO2 is one of the key indicators of pulmonary ventilation which can be obtained from arterial blood gas analysis.	30minutes and 3 hours
Secondary	Static respiratory compliance (Crs)	Crs=tidal volume/driving pressure	30minutes and 3 hours
Secondary	Cardiac output	Cardiac output assessed by echocardiography	30minutes and 3 hours
Secondary	Right ventricular function	Right ventricular function assessed by echocardiography	30minutes and 3 hours